Identifying High-Risk Myeloma - a podcast by American Society of Clinical Oncology (ASCO)

from 2014-06-02T14:46:05

:: ::

FISH genetics, LDH and beta 2-microglobulin can identify a group of newly diagnosed myeloma patients with a two-year survival of only 52% in spite of bortezomib-based therapy.